BR112015006979A2 - compostos anti-invasivos - Google Patents
compostos anti-invasivosInfo
- Publication number
- BR112015006979A2 BR112015006979A2 BR112015006979A BR112015006979A BR112015006979A2 BR 112015006979 A2 BR112015006979 A2 BR 112015006979A2 BR 112015006979 A BR112015006979 A BR 112015006979A BR 112015006979 A BR112015006979 A BR 112015006979A BR 112015006979 A2 BR112015006979 A2 BR 112015006979A2
- Authority
- BR
- Brazil
- Prior art keywords
- group
- pyrimidinyl
- pyridyl
- compounds
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
1/1 resumo compostos anti-invasivos a presente invenção diz respeito a um composto da fórmula (i): em que a e a independentemente representa um grupo fenileno ou um grupo piridileno; r2 é um átomo de hidrogênio ou um grupo alquila (c1-c4); r3 é um grupo 2-piridila, grupo 3-piridila, um grupo 4-piridila, um grupo 2-pirimidinila, um grupo 4-pirimidinila ou um grupo 5-pirimidinila; r4 é um grupo carbonila ou um grupo sulfonila; e r5 é um grupo -nh-(ch2)a-nr6r7 ou um grupo 4-metilpiperazinila, com a sendo um número inteiro de 1 a 4, r6 e r7 representando independentemente um grupo alquila (c1-c4), ou r6 e r7 juntos com o átomo de nitrogênio ao qual estão ligados formando um grupo heterociclo que é escolhido entre um grupo 4metilpiperazinila, um grupo morfolino, um grupo pirrolidinila e um grupo piperidino; ou qualquer um de seus sais farmaceuticamente aceitáveis. a invenção diz respeito ainda às composições farmacêuticas contendo um composto da fórmula (i) ou qualquer um de seus sais farmaceuticamente aceitáveis e a um processo de preparação para a obtenção do mesmo. os ditos compostos (i) são úteis para tratar câncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12186684.2 | 2012-09-28 | ||
| EP12186684.2A EP2712862A1 (en) | 2012-09-28 | 2012-09-28 | New anti-invasive compounds |
| PCT/IB2013/058992 WO2014049578A1 (en) | 2012-09-28 | 2013-09-30 | New anti-invasive compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015006979A2 true BR112015006979A2 (pt) | 2017-07-04 |
| BR112015006979B1 BR112015006979B1 (pt) | 2022-02-22 |
Family
ID=47018046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015006979-7A BR112015006979B1 (pt) | 2012-09-28 | 2013-09-30 | Compostos anti-invasivos, processo para a preparação dos mesmos e composição farmacêutica |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9969715B2 (pt) |
| EP (2) | EP2712862A1 (pt) |
| JP (1) | JP6209215B2 (pt) |
| KR (1) | KR102175775B1 (pt) |
| CN (1) | CN104903293B (pt) |
| AU (1) | AU2013322131B2 (pt) |
| BR (1) | BR112015006979B1 (pt) |
| CA (1) | CA2886804C (pt) |
| CU (1) | CU24282B1 (pt) |
| DK (1) | DK2900635T3 (pt) |
| ES (1) | ES2598056T3 (pt) |
| HK (1) | HK1213884A1 (pt) |
| HR (1) | HRP20161286T1 (pt) |
| MX (1) | MX366633B (pt) |
| PL (1) | PL2900635T3 (pt) |
| PT (1) | PT2900635T (pt) |
| RU (1) | RU2641650C2 (pt) |
| WO (1) | WO2014049578A1 (pt) |
| ZA (1) | ZA201502126B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| EP2505198A1 (en) * | 2011-04-01 | 2012-10-03 | Société Splicos | Compounds for use as therapeutic agents affecting p53 expression and/or activity |
| EP2712862A1 (en) * | 2012-09-28 | 2014-04-02 | Splicos | New anti-invasive compounds |
| MX2016005760A (es) * | 2013-11-06 | 2016-07-18 | Squibb Bristol Myers Co | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). |
| KR102412220B1 (ko) | 2013-12-24 | 2022-06-23 | 온코타르티스, 아이엔씨. | 벤즈아미드 및 니코틴아미드 화합물 및 이를 사용하는 방법 |
| EP3594205A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4423065A (en) | 1982-05-04 | 1983-12-27 | Eli Lilly And Company | Naphthalenamine insecticides |
| IL68500A (en) | 1982-05-04 | 1986-07-31 | Lilly Co Eli | N-(2,4-dinitro-6-trifluoromethylphenyl)-1-naphthylamines,their preparation and anti coccidial compositions containing them |
| KR860001567A (ko) * | 1984-08-30 | 1986-03-20 | 김순영 | 상의용 무가봉 입체 재단법 |
| EP1401427A4 (en) * | 2001-06-06 | 2004-12-01 | Agouron Pharma | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF, PROCESSES FOR THE PREPARATION THEREOF |
| EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| WO2008008234A1 (en) * | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| TW201028381A (en) * | 2008-07-14 | 2010-08-01 | Shionogi & Co | Pyridine derivative having ttk inhibition activity |
| WO2010058846A1 (ja) * | 2008-11-21 | 2010-05-27 | アステラス製薬株式会社 | ４，６-ジアミノニコチンアミド化合物 |
| FR2943669B1 (fr) | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives de nicotinamide,leur preparation et leur application en therapeutique |
| US8703768B2 (en) * | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
| EP2712862A1 (en) * | 2012-09-28 | 2014-04-02 | Splicos | New anti-invasive compounds |
-
2012
- 2012-09-28 EP EP12186684.2A patent/EP2712862A1/en not_active Withdrawn
-
2013
- 2013-09-30 ES ES13812086.0T patent/ES2598056T3/es active Active
- 2013-09-30 PT PT138120860T patent/PT2900635T/pt unknown
- 2013-09-30 KR KR1020157010969A patent/KR102175775B1/ko active IP Right Grant
- 2013-09-30 US US14/432,328 patent/US9969715B2/en active Active
- 2013-09-30 DK DK13812086.0T patent/DK2900635T3/en active
- 2013-09-30 CN CN201380060496.5A patent/CN104903293B/zh active Active
- 2013-09-30 CU CUP2015000029A patent/CU24282B1/es unknown
- 2013-09-30 JP JP2015533750A patent/JP6209215B2/ja active Active
- 2013-09-30 MX MX2015003706A patent/MX366633B/es active IP Right Grant
- 2013-09-30 CA CA2886804A patent/CA2886804C/en active Active
- 2013-09-30 BR BR112015006979-7A patent/BR112015006979B1/pt active IP Right Grant
- 2013-09-30 WO PCT/IB2013/058992 patent/WO2014049578A1/en active Application Filing
- 2013-09-30 EP EP13812086.0A patent/EP2900635B1/en active Active
- 2013-09-30 AU AU2013322131A patent/AU2013322131B2/en active Active
- 2013-09-30 PL PL13812086T patent/PL2900635T3/pl unknown
- 2013-09-30 RU RU2015115360A patent/RU2641650C2/ru active
-
2015
- 2015-03-27 ZA ZA2015/02126A patent/ZA201502126B/en unknown
-
2016
- 2016-02-18 HK HK16101763.5A patent/HK1213884A1/zh unknown
- 2016-10-06 HR HRP20161286TT patent/HRP20161286T1/hr unknown
-
2018
- 2018-04-05 US US15/946,120 patent/US10717724B2/en active Active
-
2020
- 2020-04-15 US US16/848,916 patent/US11427566B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015006979A2 (pt) | compostos anti-invasivos | |
| BRPI1010768C8 (pt) | composto de fórmula (i) | |
| EA201491824A1 (ru) | Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1 | |
| BR112012010186B8 (pt) | derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos | |
| EA201590450A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| BR112022010254A2 (pt) | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio | |
| BR112018005932A2 (pt) | inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer | |
| BR112015032921A8 (pt) | compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos | |
| BR112014027181A2 (pt) | derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1 | |
| BR112014027236A2 (pt) | pirrolidinas substituídas como um fator inibidor de xia para o tratamento de doenças tromboembolíticas | |
| BR112013020996A2 (pt) | derivados aminobutíricos substituídos como inibidores de neprilisina | |
| BR112013016856A2 (pt) | composto, uso de um composto, composição farmacêutica e produto farmacêutico | |
| BR112013001341A2 (pt) | compostos de pirimidina como inibidores de proteínas quinases ikk épsilon e/ou tbk-1, processo para a preparação dos mesmos e suas composições farmacêuticas | |
| BR112015020772A2 (pt) | compostos de pirimidina e piridina e seu uso | |
| BR112014010401A8 (pt) | Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina | |
| BR112015030515A2 (pt) | intensificadores de inibidores de homólogo 2 de zeste | |
| MX2017002986A (es) | Compuestos de piperidina sustituidos. | |
| BR112015023829A2 (pt) | composto de amidina e seu uso | |
| BR112014029439A2 (pt) | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos | |
| GB201302704D0 (en) | Therapeutic compounds | |
| CO2020005944A2 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos | |
| BR112015007641A8 (pt) | Tratamento da doença de alzheimer branda e moderada | |
| EA201600323A1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| CO7160116A2 (es) | Derivados de pirimidinona como agentes antimalaricos | |
| BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2013, OBSERVADAS AS CONDICOES LEGAIS. |